Zdrowie i gospodarka · 12/01/2018

FDA Reopens Comment Period for Draft Guidance on Abbreviated New Drug Applications and 505(b)(2) Applications

The US Food and Drug Administration (FDA) is extending the comment period for its draft guidance on abbreviated new drug applications and 505(b)(2) applications, allowing interested parties more time to provide feedback, following a request from stakeholders for an extension.